Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CONMED (CNMD)

CONMED Q4 sales rose 7.9% to $373.2 million; GAAP EPS fell to $0.54 from $1.08

Mixed Impact 4 of 5 earnings Written later

CONMED reported fourth-quarter 2025 sales of $373.2 million, up 7.9%, while GAAP diluted earnings per share fell to $0.54 from $1.08, and adjusted EPS rose to $1.43 from $1.34. For 2026, the company expects adjusted diluted EPS of $4.30 to $4.45, compared with $4.59 adjusted for full-year 2025, so shareholders face a lower adjusted earnings outlook despite higher sales.

Key points

  • Q4 2025 net sales $373.2 million, up 7.9% as reported and 7.1% in constant currency; international revenue up 17.0%, domestic up 1.4%
  • Q4 GAAP diluted EPS $0.54 vs $1.08 a year earlier; adjusted diluted EPS $1.43 vs $1.34
  • Full-year 2025 net sales $1,374.7 million, up 5.2%; GAAP diluted EPS $1.51 vs $4.25 in 2024; adjusted EPS $4.59 vs $4.17
  • 2026 outlook: reported revenue $1.345 billion to $1.375 billion and adjusted diluted EPS $4.30 to $4.45

The filing

CompanyCONMED (CNMD)
Form8-K, current report
Filed with the SECJan 28, 2026, 4:13 PM ET
Accession number0000816956-26-000006

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.